HRS-2189 + HRS-6209 + fluvastatin

**HRS-2189 + HRS-6209 + fluvastatin** is an investigational oral combination regimen currently undergoing evaluation in phase 1/2 clinical trials for **advanced unresectable or metastatic breast cancer**[3][4][6]. - **HRS-2189** is a small molecule drug under study for anti-tumor activity; its detailed target and mechanism have not been publicly disclosed, but it is being developed specifically for malignant solid tumors including breast cancer[2][3]. - **HRS-6209** is a small molecule inhibitor selectively targeting **Cyclin-dependent kinase 4 (CDK4)**, acting as a CDK4 inhibitor for anti-proliferative activity against tumor cells, also under development for breast cancer and solid tumors[1]. - **Fluvastatin** is a well-established oral small molecule, a competitive **HMG-CoA reductase inhibitor** (statin class), approved for hypercholesterolemia; as part of this regimen, it may be added for potential anti-tumor effects in combination settings. Current clinical trials investigate this combination for preliminary efficacy, pharmacokinetics, and safety in breast cancer patients who are advanced or metastatic, with sponsors including Jiangsu Hengrui Pharmaceuticals and Shandong Suncadia Medicine.